pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Bispecific Antibody · news · pharmadog
← back to Bispecific Antibody
News · Bispecific Antibody
151
stories
1d
Chai tees up Bristol Myers Squibb AI antibody discovery collab
fiercebiotech
1d
Why Pheast’s CEO has no regrets about transparent approach to R&D despite competitors circling
fiercebiotech
2d
Bristol Myers' partner Biokin says bispecific ADC clears fourth cancer trial in China
endpoints
2d
Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more
biospace
4d
AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer
biopharma dive
4d
Summit, Akeso's ivonescimab shows smaller benefit with longer follow-up in China
endpoints
4d
Summit, Akeso’s China approval celebration cut short as survival benefit degrades
biospace
4d
Regeneron ends eye disease trial for anti-CD3 antibody following safety review
fiercebiotech
4d
AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow
biospace
4d
AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow
biospace
4d
J&J hands lymphoma bispecific CAR T back to AbelZeta
biospace
4d
Slate uses Fulcrum to vault onto Nasdaq with $245M financing for migraine trials
fiercebiotech
4d
Lilly pens $370M deal with OmniAb for ion channel collab, but details remain vague
fiercebiotech
4d
AstraZeneca ends phase 3 lung cancer trial after bispecific falls short versus Keytruda
fiercebiotech
7d
Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers
biopharma dive
8d
Taiho and Cullinan’s zipalertinib clears Phase 3, teeing up first-line competition
biospace
8d
PDS halts work on phase 3 cancer therapy to focus on colorectal contender
fiercebiotech
8d
Cullinan tees up J&J fight—and $100M payday—as Taiho-partnered drug hits phase 3 cancer goal
fiercebiotech
9d
Boulevard starts up with $65M to pursue targeted autoimmune drugs
biopharma dive
10d
Chasing Dupixent, a biotech aims to make better antibody drugs for eczema
biopharma dive
10d
Deerfield-backed Boulevard Bio embarks on ‘beautiful path to a cure’ with trio of immunology drugs
fiercebiotech
10d
After tasting IPO success, Hemab’s CEO seeks ‘flavor of a multi-product coagulation company’
fiercebiotech
11d
‘We are proud to be in the lead’: Vaderis lands $152M for phase 3 study in rare blood vessel disorder
fiercebiotech
11d
Scholar Rock ditches Novo’s legacy Catalent plant in FDA refiling of SMA drug
fiercebiotech
15d
Context scraps bispecific T-cell engager program to extend cash runway deeper into 2027
fiercebiotech
16d
Attovia's CEO aims to scratch itch opportunity and challenge Dupixent with $289M IPO
fiercebiotech
17d
J&J pharma leader to retire; Krystal slumps on gene therapy miss
biopharma dive
17d
Pathos inks back-to-back cancer contracts with AstraZeneca, China’s Alphamab
biospace
17d
Pathos AI pads pipeline with $2.2B Alphamab deal, AstraZeneca pact
fiercebiotech
18d
BioNTech taps Sobi executive Oelkers as its next CEO
biopharma dive
← prev
page 1 of 6
next →
